onc Videos

Videos

Videos

Novel Agents for Managing Patients With Relapsed ALL

10/19/2022

Michal Bar-Natan, MD, provides an update on the newest agents for management of relapsed ALL at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Michal Bar-Natan, MD, provides...

10/19/2022

Oncology

Videos

Current and Future Treatment Paradigms in Second-Line Endometrial Cancer

10/19/2022

BJ Rimel, MD, shares new and upcoming treatments in the second-line setting for patients with endometrial cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

BJ Rimel, MD, shares new and...

10/19/2022

Oncology

Videos

Considerations When Treating Premenopausal Patients With Breast Cancer

10/19/2022

Matteo Lambertini, MD, PhD, discusses insights, strategies, and potential complications when treating a younger patient with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.

Matteo Lambertini, MD, PhD,...

10/19/2022

Oncology

Elias Jabbour, MD, MD Anderson Cancer Center

Videos

Incorporation of Antibodies Into the Management of Upfront and Relapsed ALL

10/19/2022

Elias Jabbour, MD, provides an update on the incorporation of antibodies into the management of upfront and relapsed ALL.

Elias Jabbour, MD, provides an...

10/19/2022

Oncology

Videos

Management of CML: New Agents and Monitoring for MRD

10/19/2022

Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.

Ehab Atallah, MD, provides an...

10/19/2022

Oncology

Axel Bex, MD, Netherlands Cancer Institute

Videos

Adjuvant Atezolizumab vs Placebo Following Nephrectomy for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

10/19/2022

Axel Bex, MD, reviews results from the phase 3 IMmotion010 trial showing no benefit to clinical outcomes with adjuvant atezolizumab vs placebo following nephrectomy for patients with renal cell carcinoma and an increased risk of recurrence.

Axel Bex, MD, reviews results...

10/19/2022

Oncology

Fred Saad, MD, University of Montréal Hospital Center

Videos

Olaparib Prolongs Radiographic PFS vs Placebo in Metastatic Castration-Resistant Prostate Cancer Across Subgroups

10/18/2022

Fred Saad, MD, discusses findings from a biomarker analysis of the phase 3 PROpel trial investigating abiraterone plus olaparib vs abiraterone plus placebo for patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, discusses...

10/18/2022

Oncology

Paolo Ascierto, MD, National Cancer Institute, Naples, Italy

Videos

What is the Best Sequencing of Targeted Therapy and Immunotherapy for Metastatic BRAFV600-Mutated Melanoma?

10/18/2022

Paolo Ascierto, MD, reviews 4-year data and a preliminary biomarker analysis from a phase 2 trial exploring the ideal sequential strategy of targeted therapy and immunotherapy for patients with untreated, metastatic BRAFV60-mutated melanoma.

Paolo Ascierto, MD, reviews...

10/18/2022

Oncology

Videos

Nivolumab Plus Ipilimumab in the First-Line and Salvage Settings for Advanced Merkel Cell Carcinoma

10/18/2022

Sungjune Kim, MD, PhD, shares insights from a randomized phase 2 trial exploring first-line combination therapy with nivolumab and ipilimumab for patients with advanced Merkel cell carcinoma, first presented at the 2022 ESMO Congress.

Sungjune Kim, MD, PhD, shares...

10/18/2022

Oncology

Videos

Caring for Transgender and Special Population Patients as an Oncologist

10/17/2022

BJ Rimel, MD, shares important tips and insights regarding the care for transgender and special population patients being treated for cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

BJ Rimel, MD, shares important...

10/17/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology